Aspire IRB
Aspire IRB is an independent institutional review board founded in 2004 in Santee, California, providing ethical and regulatory review services for clinical research studies across pharmaceutical, biotech, medical device, academic, and behavioral research sponsors.
- Company typePrivate
- Founded1969
- HeadquartersSantee, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Aspire IRB does
Aspire IRB is an independent institutional review board (IRB) founded in 2004 and headquartered in Santee, California. It provides ethical and regulatory review services for clinical research studies conducted across pharmaceutical, biotechnology, medical device, academic, and social/behavioral research settings. The firmographic profile indicates a small biotech-stage entity with 11-50 employees.
The detailed operational evidence available for the broader WCG Clinical IRB infrastructure (with which Aspire IRB is associated) shows a review capability built around a panel of nearly 200 IRB professionals, supported by Board Certified IRB Professionals (CIPs) and accredited under AAHRPP and ISO 9001 standards. Service offerings span central IRB review, IRB reliance and cede/review arrangements, specialized therapeutic-area boards (Oncology, CNS, Cardiovascular, Medical Device, Social/Behavioral), and ancillary compliance services such as biosafety, conflict-of-interest review, and IBC administration. The technology stack includes proprietary platforms ClinSphere (with a Trial IntelX insights module), IRBNet, and an ePay system for fee processing, alongside a Central Sites Network that connects reviewed protocols to clinical trial sites. Operations run 7 days a week, 365 days a year.
The business model is fee-for-service, with quote-based, customized pricing per study and engagement-based multi-year contracting for enterprise sponsors. Go-to-market is anchored on direct relationships with large pharma (Genentech), global CROs (PPD), academic medical centers, and federal/non-federal grant-funded researchers. Revenue mechanics derive from per-study review fees, ancillary service charges, and platform access for sponsor and site workflow management. Geographic reach includes U.S. coverage and a Canadian IRB board serving cross-border trials, with a Phase I capability added via a partnership with Dr. Vince Clinical Research.
Aspire IRB firmographics
Firmographics- Name
- Aspire IRB
- Legal name
- WCG Clinical
- Website
- https://aspire-irb.com
- Company type
- Private
- Founded year
- 1969
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aspire IRB is an independent institutional review board founded in 2004 in Santee, California, providing ethical and regulatory review services for clinical research studies across pharmaceutical, biotech, medical device, academic, and behavioral research sponsors.
- Ownership category
- akta.pro rank
Aspire IRB industry classification
Industry- Product category
- Clinical Research Ethics Review (IRB Services)
- NAICS
- Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Computer Programming Services (7371)
- akta.pro primary industry
- Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)
- akta.pro secondary industry
- Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH)
Keywords
Where Aspire IRB is headquartered
LocationHeadquarters
- HQ city
- Santee
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aspire IRB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- IRB Review Services: Fee-based ethical review services for clinical research studies including pharmaceutical trials, medical device studies, biologics research, and pediatric studies. Revenue generated through per-study review fees with various service tiers including standard and accelerated (IRB+) options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Standard IRB Review |
| Other | Multi-year contract | IRB+ Accelerated Service |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Aspire IRB product offering
Product offeringCore offering
Aspire IRB provides independent ethical review (IRB) services for clinical research studies, covering pharmaceutical trials, medical device studies, biologics research, pediatric research, and social/behavioral studies. Services include standard IRB review plus an accelerated IRB+ tier with white-glove expedited processing. The company also delivers Institutional Biosafety Committee (IBC) review services for studies involving gene transfer and biologics, supported by submission portals such as ClinSphere and eReview Manager.
Product overview
WCG (formerly WCG Clinical) operates as a unified platform-plus-services provider for the clinical research industry, centered on its ClinSphere™ platform which integrates multiple sub-products including eReview Manager, AIMS®, IRBNet, InvestigatorSpace®, and Trial IntelX™. The company's core offering is IRB Review services augmented by specialized review services for pharmaceuticals, medical devices, biologics, pediatrics, and social/behavioral research. Additional technology solutions include Total Enrollment, Total Feasibility, eResearch Enterprise CTMS, and Clinical Trial Listing Service. The portfolio also encompasses study enablement services such as participant recruitment, clinical trial training, site network access, and data monitoring committees, all designed to accelerate clinical trial timelines from study planning through completion.
Differentiator
Problem solved
Functional benefit
Brands
- ClinSphere eReview Manager: Modern user interface for IRB review workflows with real-time collaboration and efficiency features.
- IRB+
Products and services
- IRB Review Independent ethical review service for clinical research protocols, utilizing a custom board of nearly 200 WCG IRB experts augmented by an extensive clinical advisory network to provide swift protocol determinations for sponsors and investigators.
- IRB+ Accelerated Service Accelerated IRB review service with white-glove support for studies requiring expedited processing, enabling faster study start-up without compromising quality and integrity of ethical review.
- IBC Review Institutional Biosafety Committee review services for clinical studies involving biologics, gene transfer protocols, CAR-T, T-cells, B-cells, stem cells, viral vectors, and other biological materials manufactured from living cells and tissue.
- Canadian Board Review Comprehensive ethical review services for clinical studies conducted within Canadian Provinces, compliant with Health Canada Division 5 regulations, with board members who are Canadian citizens or permanent residents.
- Pediatric IRB Review Specialized IRB review for clinical research involving children as subjects, including parental permission documentation, child assent forms, and four categories of pediatric research approval with additional regulatory and ethical protections.
Quantifiable outcome
- Less than 6 days for new protocol determinations from submission to document delivery
- +2 more outcomes
Companies that use Aspire IRB
Customer profileNamed customers3 records
Segments7 records
Ideal customer profiles4 records
Aspire IRB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Aspire IRB partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dr. Vince Clinical ResearchcoreStrategic partnership to expand Phase I review services. Dr. Vince Clinical Research brings Phase I investigator expertise to enhance WCG's review capabilities for first-in-human studies and residential clinical trials requiring extended monitoring.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
Aspire IRB competitors and assessment
Company assessmentDirect peers
- Advarra: Formed from the merger of Chesapeake IRB and Schulman IRB (later absorbing Quorum Review IRB), Advarra is the other dominant independent central IRB serving pharma, device, and academic sponsors with overlapping IRB, IBC, and research compliance services.
- IntegReview IRB: An AAHRPP-accredited independent central IRB offering ethical review for clinical trials across multiple therapeutic areas, competing head-to-head with WCG for sponsor review contracts.
- Quorum Review IRB / Kinetiq: A long-standing independent central IRB (Quorum) that spun out its ethical-review business into Kinetiq, offering IRB and IBC services for clinical research sponsors across North America.
- Sterling IRB: An independent central IRB providing protocol review services for pharmaceutical, device, and behavioral research — a direct competitor in the same central IRB category as WCG.
Broad incumbents
- ICON plc: A top global CRO whose post-2021 PRA Health Sciences acquisition created a broad clinical services portfolio overlapping with WCG's IRB-adjacent technology, feasibility, and trial enablement offerings.
- IQVIA: The world's largest CRO, offering a broad portfolio of clinical trial services that includes IRB coordination and ethics oversight as part of its integrated biopharma services — competing with WCG's ClinSphere platform ambitions.
- Labcorp Drug Development (formerly Covance): A major central laboratory and clinical development services provider whose clinical trial offerings overlap with WCG's study-enablement and central review-adjacent services for sponsors and CROs.
- Charles River Laboratories: A large preclinical and clinical services provider whose Discovery & Safety Assessment and clinical manufacturing offerings intersect with WCG's biologics/IBC review work and broader clinical research support.
Emerging players
- Clario: A clinical trial technology vendor (formed from ERT and Bioclinica) offering eCOA, imaging, and trial-management platforms that compete with WCG's ClinSphere platform and adjacent study-enablement technology stack.
- BRANY (Biomedical Research Alliance of New York): A consortium-based IRB serving academic medical centers and industry sponsors with central IRB services, particularly in the Northeast US, directly overlapping WCG's academic and hospital-facing review work.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Aspire IRB social profiles
Digital presenceAspire IRB compliance and trust
Trust signalCompliance2 records
Aspire IRB financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspire IRB leadership team
Management profileNumber of profiles
Profiles1 record
Aspire IRB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspire IRB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspire IRB
What does Aspire IRB do?
Aspire IRB provides independent ethical review (IRB) services for clinical research studies, covering pharmaceutical trials, medical device studies, biologics research, pediatric research, and social/behavioral studies. Services include standard IRB review plus an accelerated IRB+ tier with white-glove expedited processing. The company also delivers Institutional Biosafety Committee (IBC) review services for studies involving gene transfer and biologics, supported by submission portals such as ClinSphere and eReview Manager.
Is Aspire IRB a public or private company?
Aspire IRB is a private company. It is classified as unknown and is currently operating.
When was Aspire IRB founded?
Aspire IRB was founded in 1969. It employs 11 to 50 people.
Where is Aspire IRB based?
Aspire IRB is headquartered in Santee, United States, in the North America region.
How does Aspire IRB make money?
One revenue line is on record: IRB Review Services.
Who are Aspire IRB's main competitors?
Direct peers on record are Advarra, IntegReview IRB, Quorum Review IRB / Kinetiq and Sterling IRB. Broad incumbents are ICON plc, IQVIA, Labcorp Drug Development (formerly Covance) and Charles River Laboratories. Emerging players are Clario and BRANY (Biomedical Research Alliance of New York).
Does Aspire IRB have an API?
No public API is recorded for Aspire IRB.
What industry is Aspire IRB in?
Aspire IRB's product category is Clinical Research Ethics Review (IRB Services). Its primary akta.pro industry code is HLAJACAG, Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight), with a secondary code of EDADAKAH, Research Administration & Compliance (Sponsored Programs, IRB/REB). Its NAICS code is 541690 and its SIC code is 7371.